Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial
Article in JCO Global Oncology (January 2024)
The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.
Risk factors for the development of hematological toxicity during the application of weekly paclitaxel in breast cancer
Article in Gaceta Mexicana de Oncolog�a (September 2022)
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA
Article in Advances in Therapy (August 2022)